Learn more about TABRECTA
For US residents only.
Testing and Diagnosis
METex14 in Metastatic Non-Small Cell Lung Cancer
Knowing more about your cancer can help inform treatment options
Gene changes (mutations), like the ones that lead to MET exon 14 skipping (METex14), are linked to cancer growth, and are common in metastatic non-small cell lung cancer (mNSCLC).
If you’re currently taking TABRECTA™ (capmatinib) tablets, your tumor has already been tested and found to be positive for METex14.
What is biomarker testing?
Biomarker testing (also called genetic testing) can help you find out more about your type of lung cancer. This kind of test looks for gene mutations in your DNA, which can help your doctor find an appropriate treatment option for you.
Comprehensive biomarker tests look for multiple genetic mutations that may be found in your type of cancer in one test, including mutations that lead to METex14.
If you’ve already had tumor tissue removed during biopsy or surgery, the tissue may be used for this test.
The results of your test can help you and your doctor find a treatment that specifically targets your cancer. Ask your doctor about taking a comprehensive biomarker test.